🏛️ Verified NIH Protocol • Sourced via U.S. National Library of Medicine (Last Synced: 2026-03-20)

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

🟢 Recruiting Phase 2 💊 Investigational Drug / Biologic Sponsor: SCRI Development Innovations, LLC

🩺 Protocol Summary

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil

Primary Research Facility: Maryland Oncology Hematology (Columbia, Maryland)

📋 Preliminary Self-Screener

0 of 3 Answered

Answer all 3 basic criteria below to see your preliminary screening result:

Diagnosed with or currently undergoing clinical evaluation for **Breast Neoplasms**?

Aged **18 Years or older**?

Able to attend study appointments at **Maryland Oncology Hematology** (Columbia, Maryland) or affiliated sites?

📍 Primary Site Map

Site: Maryland Oncology Hematology — Columbia, Maryland

📍 All Participating Trial Locations (8 Sites)

Multi-Center Trial

This protocol is enrolling participants across multiple clinical centers:

1. Maryland Oncology Hematology — Columbia, Maryland

2. Alliance Cancer Specialists — Bensalem, Pennsylvania

3. SCRI Oncology Partners — Nashville, Tennessee

4. Tennessee Oncology — Nashville, Tennessee

5. Texas Oncology- DFW — Dallas, Texas

6. Texas Oncology- San Antonio — San Antonio, Texas

7. Virginia Oncology Associates — Norfolk, Virginia

8. Blue Ridge Cancer Care (Oncology & Hematology Assoc of SW Virginia, Inc) — Salem, Virginia

📄 Print Doctor Discussion Sheet

Preview and print a 1-page summary with 5 tailored questions for your physician.

💰 Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.

🏛️ Official Government Provenance

NIH ClinicalTrials.gov Protocol Record

NCT Identifier: NCT05748834 • Last Synced: 2026-03-20

View on ClinicalTrials.gov ↗